5F-AB-FUPPYCA

5F-AB-FUPPYCA (also known as AZ-037) is a pyrazole-based synthetic cannabinoid that is presumed to be an agonist of the CB1 receptor and has been sold online as a designer drug. It was first detected by the EMCDDA as part of a seizure of 540 g white powder in France in February 2015.

The name AZ-037 is also used as a synonym for its structural isomer 5-fluoro-3,5-AB-PFUPPYCA. Thus AZ-037 is being used as a synonym for two different compounds.

5-fluoro-3,5-AB-PFUPPYCA has been detected in synthetic cannabinoid smoke blends in the USA as early as December 30, 2021, along with ADB-BUTINACA, MDA-19 (BZO-HEXOXIZID) and MDMB-4en-PINACA.

5-fluoro-AB-PFUPPYCA contains some similar structural elements to other synthetic cannabinoids such as AB-CHFUPYCA, JWH-307, JWH-030, JWH-147, AB-PINACA. It may be considered an analog of the traditional pyrazole cannabinoid receptor 1 antagonist rimonabant. The pharmacological properties of 5F-AB-FUPPYCA have not been studied.

Legality
In the United States, 5F-AB-FUPPYCA is unscheduled at the federal level as of May 22, 2023. It's possible that it may be considered under the federal analogue act as a functional analog due to pharmacology or as a distant structural analog of JWH-307.

North Dakota has placed 5F-AB-FUPPYCA (N-(1-carbamoyl-2-methyl-propyl)-2-(5-fluoropentyl)-5-(4-fluorophenyl)pyrazole-3-carboxamide) into Schedule I status on 04/27/2023. However, this did not include structural substitutions it gave to other cannabinoid structural classes. As such does not include other pyrazoles analogs such as the non-fluorinated AB-FUPPYCA analog.